Bortezomib latest market price trend analysis in 2025

As of 2025, the price trend of Bortezomib in the Chinese market has shown diversified development, which is mainly affected by factors such as the launch time of the original drug, medical insurance policies, generic drug competition, and international market dynamics.

In China, the common specifications of the original drug bortezomib are 2mg and 3.5mg, with a price of about RMB 3,000 per box. It has been included in the national medical insurance catalog, and patients can enjoy medical insurance reimbursement. With the improvement of medical insurance payment policies and the advancement of centralized drug procurement, the price of original drugs may drop to a certain extent to improve patient accessibility and treatment compliance.

At the same time, the generic drug bortezomib is gradually increasing in the Chinese market, mainly produced by pharmaceutical companies in India and other countries. The ingredients of these generic drugs are basically the same as those of the original drugs, but due to low production costs, the price is usually more than 1,000 yuan per box. The price may fluctuate due to exchange rate fluctuations. The emergence of generic drugs provides patients with more choices and promotes market competition, helping to reduce overall treatment costs.
In the international market, the price trend of bortezomib is also showing growth. According to market research, the global bortezomib market is expected to reach US$25.7 million in 2025 and grow to US$35.2 million in 2032, with an average annual growth rate of approximately 4.6%. This growth was primarily driven by an increase in the number of patients in indications such as multiple myeloma and rising demand for treatment.
To sum up, the price of bortezomib in the Chinese market in 2025 will show a pattern of coexistence of original drugs and generic drugs. The improvement of medical insurance policies and the intensification of market competition are expected to further reduce the economic burden on patients. In the future, with the expansion of treatment indications and the improvement of production processes, the market prospects of bortezomib will still be broad.
Reference: https://www.fda.gov/drugs/